TC
SRRA

TFS Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

TFS Capital’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-387
Closed -$24K – 822
2017
Q1 		$24K Buy
+387
New +$22.5K 0.01% 639

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

TFS Capital's SRRA Position: Q2 2017 in Review

TFS Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2017, closing a stake of 387 shares — an estimated $24K sold.

TFS Capital first reported a position in SRRA in Q1 2017 and held it in 1 quarter. The position peaked at $24K in Q1 2017. 40 funds tracked by Wall St. Rank hold SRRA as of Q2 2017.

  • TFS Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 387 Sierra Oncology, Inc. Common Stock shares in Q2 2017, an estimated $24K.
  • TFS Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • TFS Capital's Sierra Oncology, Inc. Common Stock position peaked at $24K in Q1 2017.
  • 40 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.